Versant Capital Management Inc Acquires 326 Shares of Edwards Lifesciences Co. (NYSE:EW)

Versant Capital Management Inc lifted its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 206.3% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 484 shares of the medical research company’s stock after acquiring an additional 326 shares during the quarter. Versant Capital Management Inc’s holdings in Edwards Lifesciences were worth $45,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in EW. DSM Capital Partners LLC bought a new position in shares of Edwards Lifesciences during the fourth quarter valued at approximately $28,000. Crewe Advisors LLC bought a new position in Edwards Lifesciences in the first quarter worth $28,000. Turtle Creek Wealth Advisors LLC bought a new position in Edwards Lifesciences in the fourth quarter worth $34,000. Riverview Trust Co bought a new position in Edwards Lifesciences in the first quarter worth $34,000. Finally, Pingora Partners LLC bought a new position in Edwards Lifesciences in the fourth quarter worth $38,000. Institutional investors own 79.46% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on EW shares. Canaccord Genuity Group decreased their price objective on Edwards Lifesciences from $85.00 to $77.00 and set a “hold” rating for the company in a report on Thursday, July 25th. JPMorgan Chase & Co. cut Edwards Lifesciences from an “overweight” rating to a “neutral” rating and cut their target price for the stock from $105.00 to $72.00 in a research note on Thursday, July 25th. Wolfe Research raised Edwards Lifesciences from an “underperform” rating to a “peer perform” rating in a research note on Monday, July 29th. Bank of America cut Edwards Lifesciences from a “buy” rating to a “neutral” rating and cut their target price for the stock from $105.00 to $75.00 in a research note on Thursday, July 25th. Finally, Wells Fargo & Company cut their target price on Edwards Lifesciences from $99.00 to $90.00 and set an “overweight” rating on the stock in a research note on Thursday, July 25th. Fourteen equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $82.10.

Edwards Lifesciences Stock Performance

NYSE:EW traded up $1.23 on Tuesday, hitting $61.93. The stock had a trading volume of 6,925,647 shares, compared to its average volume of 3,975,926. The stock has a market cap of $37.31 billion, a price-to-earnings ratio of 27.04, a price-to-earnings-growth ratio of 2.57 and a beta of 1.11. The company has a quick ratio of 2.87, a current ratio of 3.71 and a debt-to-equity ratio of 0.08. The business’s 50-day simple moving average is $84.78 and its two-hundred day simple moving average is $86.49. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $96.12.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Wednesday, July 24th. The medical research company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.69 by $0.01. Edwards Lifesciences had a return on equity of 22.35% and a net margin of 24.55%. The firm had revenue of $1.63 billion for the quarter, compared to the consensus estimate of $1.65 billion. During the same quarter last year, the company earned $0.66 earnings per share. The business’s revenue for the quarter was up 6.7% compared to the same quarter last year. As a group, research analysts predict that Edwards Lifesciences Co. will post 2.71 earnings per share for the current year.

Insider Transactions at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction dated Friday, May 10th. The stock was sold at an average price of $87.81, for a total value of $439,050.00. Following the transaction, the vice president now owns 47,750 shares of the company’s stock, valued at $4,192,927.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, CFO Scott B. Ullem sold 5,625 shares of Edwards Lifesciences stock in a transaction that occurred on Tuesday, May 21st. The stock was sold at an average price of $90.45, for a total transaction of $508,781.25. Following the sale, the chief financial officer now owns 30,561 shares of the company’s stock, valued at approximately $2,764,242.45. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction that occurred on Friday, May 10th. The shares were sold at an average price of $87.81, for a total value of $439,050.00. Following the sale, the vice president now directly owns 47,750 shares in the company, valued at approximately $4,192,927.50. The disclosure for this sale can be found here. Insiders have sold 29,242 shares of company stock valued at $2,607,520 over the last quarter. 1.29% of the stock is currently owned by company insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.